Abstract: The invention is directed to a formula (I): or a pharmaceutically acceptable salt thereof, wherein R1, R2a, R2b and R3-R7 are herein. The invention is also directed to compositions containing a compound of formula (I) and to the use of such compounds in the inhibition of mutant IDH proteins having a neomorphic activity. The invention is further directed to the use of a compound of formula (I) in the treatment of diseases or disorders associated with such mutant IDH proteins including, but not limited to, cell-proliferation disorders, such as cancer.

Abstract: A method and apparatus for initiating secure operations in a microprocessor system is described. In one embodiment, one initiating logical processor initiates the process by halting the execution of the other logical processors, and then loading initialization and secure virtual machine monitor software into memory. The initiating processor then loads the initialization software into secure memory for authentication and execution. The initialization software then authenticates and registers the secure virtual machine monitor software prior to secure system operations.

Abstract: In one embodiment of the present invention, a method includes verifying a master processor of a system; validating a trusted agent with the master processor if the master processor is verified; and launching the trusted agent on a plurality of processors of the system if the trusted agent is validated. After execution of such a trusted agent, a secure kernel may then be launched, in certain embodiments. The system may be a multiprocessor server system having a partially or fully connected topology with arbitrary point-to-point interconnects, for example.

Abstract: In one embodiment of the present invention, a method includes verifying a master processor of a system; validating a trusted agent with the master processor if the master processor is verified; and launching the trusted agent on a plurality of processors of the system if the trusted agent is validated. After execution of such a trusted agent, a secure kernel may then be launched, in certain embodiments. The system may be a multiprocessor server system having a partially or fully connected topology with arbitrary point-to-point interconnects, for example.

Abstract: A method and apparatus is described herein for supporting direct memory accesses between peer I/O devices. It is determined whether a guest physical address (GPA) referenced by an access generated from an I/O device, is within a range of GPAs associated with local I/O devices based at least in part on a GPA base and a GPA window size. If the GPA is within the window, then the GPA is translated to an HPA based at least in part on a base HPA associated with a local device and then forwarded to that local device. However, if the GPA is not within the window, then the access is forwarded upstream.

Abstract: The present invention provides a compound of formula (I): and pharmaceutically acceptable salts, enantiomers, stereoisomers, rotamers, tautomers, diastereomers, or racemates thereof. Also provided is a method of treating a disease or condition mediated by CDK9.

Abstract: The invention is directed to a formula (I): or a pharmaceutically acceptable salt thereof, wherein R1, R2a, R2b and R3-R7 are herein. The invention is also directed to compositions containing a compound of formula (I) and to the use of such compounds in the inhibition of mutant IDH proteins having a neomorphic activity. The invention is further directed to the use of a compound of formula (I) in the treatment of diseases or disorders associated with such mutant IDH proteins including, but not limited to, cell-proliferation disorders, such as cancer.

Abstract: System, method and computer readable media embodiments are disclosed for performing event based analysis where a first query is performed on a first data source to obtain a first set of records based on a first event and a second query (independent from the first query) is performed on a second data source to obtain a second set of records based on a second event. Each set of records includes analysis dimension variable and a time dimension. A result set is generated by combining the first and second sets of records to find an intersection of the two sets based at least partly on the time dimension variables. A binary mapping is generated from the result set to establish a distinct set of values of the analysis dimension variable that match the intersection of the two sets.

Abstract: A method and apparatus for initiating secure operations in a microprocessor system is described. In one embodiment, one initiating logical processor initiates the process by halting the execution of the other logical processors, and then loading initialization and secure virtual machine monitor software into memory. The initiating processor then loads the initialization software into secure memory for authentication and execution. The initialization software then authenticates and registers the secure virtual machine monitor software prior to secure system operations.

Abstract: The present invention provides a compound of formula (I): and pharmaceutically acceptable salts, enantiomers, stereoisomers, rotamers, tautomers, diastereomers, or racemates thereof. Also provided is a method of treating a disease or condition mediated by CDK9.

Abstract: The invention provides a method of aggregate banding comprising defining an aggregate banding dimension for a first data source, the aggregate banding dimension including at least one aggregation variable, at least one banding variable, and at least one band based at least partly on the at least one banding variable; summarizing the data source based at least partly on the at least one aggregation variable, the summary including at least one distinct value of the at least one aggregation variable; and defining a mapping relationship of the at least one distinct value of the at least one aggregation variable to the or respective band(s) based on the value of the at least one banding variable. The invention further provides related systems and processor-executable instructions.

Abstract: A method and apparatus is described herein for supporting direct memory accesses between peer I/O devices. It is determined whether a guest physical address (GPA) referenced by an access generated from an I/O device, is within a range of GPAs associated with local I/O devices based at least in part on a GPA base and a GPA window size. If the GPA is within the window, then the GPA is translated to an HPA based at least in part on a base HPA associated with a local device and then forwarded to that local device. However, if the GPA is not within the window, then the access is forwarded upstream.

Abstract: Apparatuses, methods, and systems for reconfiguring a secure system are disclosed. In one embodiment, an apparatus includes a configuration storage location, a lock, and lock override logic. The configuration storage location is to store information to configure the apparatus. The lock is to prevent writes to the configuration storage location. The lock override logic is to allow instructions executed from sub-operating mode code to override the lock.

Abstract: The present invention provides a compound of formula I; wherein R1 is an alkyl pyrazole or an alkyl carboxamide, and R2 is a hydroxycycloalkyl; or a pharmaceutically acceptable salt thereof, and compositions containing these compounds, for use to treat a brain tumor, particularly glioblastoma. The invention provides effective treatment of a brain tumor and can be used by oral administration of a compound of Formula I as further described herein. The invention also provides a method to treat a subject having a brain tumor such as glioblastoma, wherein the method comprises administering to the subject an effective amount of a compound of Formula I. Gene signatures correlated with successful treatment using these methods are also disclosed.

Abstract: Delivering a Direct Proof private key to a device installed in a client computer system in the field may be accomplished in a secure manner without requiring significant non-volatile storage in the device. A unique pseudo-random value is generated and stored in the device at manufacturing time. The pseudo-random value is used to generate a symmetric key for encrypting a data structure holding a Direct Proof private key and a private key digest associated with the device. The resulting encrypted data structure is stored on a protected on-line server accessible by the client computer system.

Abstract: A method and apparatus for initiating secure operations in a microprocessor system is described. In one embodiment, one initiating logical processor initiates the process by halting the execution of the other logical processors, and then loading initialization and secure virtual machine monitor software into memory. The initiating processor then loads the initialization software into secure memory for authentication and execution. The initialization software then authenticates and registers the secure virtual machine monitor software prior to secure system operations.

Abstract: The invention provides methods of monitoring differential gene expression of pharmacodynamic (PD) markers in a patient treated with a Cyclin Dependent Kinase Inhibitor (CDKI), methods of determining the sensitivity of a cell to a CDKI by measuring PD markers and methods of screening for candidate CKDI.

Abstract: The present invention provides a compound of formula (I): and pharmaceutically acceptable salts, enantiomers, stereoisomers, rotamers, tautomers, diastereomers, or racemates thereof. Also provided are pharmaceutical compositions containing these compounds and methods of treating a disease or condition mediated by CDK9 using these compounds and compositions.

Abstract: The present invention provides a compound of formula (II): where R1 is a substituted alkyl, heterocyclic, or cycloalkyl, group, and pharmaceutically acceptable salts, enantiomers, stereoisomers, rotamers, tautomers, diastereomers, or racemates thereof, and pharmaceutical compositions comprising these compounds. Also provided are methods of using these compounds to treat a disease or condition mediated by CDK9, such as cancers and other conditions described herein.

Abstract: In one embodiment of the present invention, a method includes verifying a master processor of a system; validating a trusted agent with the master processor if the master processor is verified; and launching the trusted agent on a plurality of processors of the system if the trusted agent is validated. After execution of such a trusted agent, a secure kernel may then be launched, in certain embodiments. The system may be a multiprocessor server system having a partially or fully connected topology with arbitrary point-to-point interconnects, for example.